Acadia Pharmaceuticals Inc.
$4.96B- Market cap
- $4.83B
- Debt
- +$306.51M
- Cash
- −$177.70M
Capital structure 94% equity / 6% debt · EV / Revenue 4.63x · EV / EBITDA 32.90x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ACAD stock price vs VIAV: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VIAV's multiple
Needs VIAV P/E.
Implied fair value · at ACAD's multiple
Needs EPS (TTM) is negative, ACAD P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ACAD FY 2025 (ended Dec 31, 2025) · VIAV FY 2026 (ended Jun 27, 2026). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 4.63x · EV / EBITDA 32.90x
Capital structure 97% equity / 3% debt · EV / Revenue 5.40x · EV / EBITDA 66.86x
VIAV carries the larger enterprise value at $8.20B against $4.96B; ACAD trades on the lower EV / Revenue multiple (4.63x vs 5.40x); ACAD on the lower EV / EBITDA (32.90x vs 66.86x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ACADIA PHARMACEUTICALS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Viavi Solutions Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.25x
0.17x
Net debt / EBITDA
Leverage against operating earnings
0.85x
-3.30x
Cash and equivalents
Liquid reserves on the balance sheet
$177.70M
$649.80M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
ACAD vs SUPN
Sage Therapeutics, Inc.
ACAD vs SAGE
Jazz Pharmaceuticals plc
ACAD vs JAZZ
Alkermes plc.
ACAD vs ALKS
Harmony Biosciences Holdings, Inc.
ACAD vs HRMY
Krystal Biotech, Inc.
ACAD vs KRYS
Broadcom Inc.
ACAD vs AVGO
TEXAS INSTRUMENTS INC
ACAD vs TXN
ANALOG DEVICES INC
ACAD vs ADI
SKYWORKS SOLUTIONS, INC.
ACAD vs SWKS
Qorvo, Inc.
ACAD vs QRVO
Marvell Technology, Inc.
ACAD vs MRVL
$306.51M
$244.80M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.